SLNSW-SGLT-2 Inhibition with Dapagliflozin Reduces the ...-TN_cdi_proquest_journals_1899705173

SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor

Full title: SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor

Author/creator: Ye, Yumei, Bajaj, Mandeep, Yang, Hsiu-Chiung, Perez-Polo, Jose R., Birnbaum, Yochai.

Call Numbers:

Record Identifier: TN_cdi_proquest_journals_1899705173

Language: English

Formats: Articles

Publishers: New York: Springer US

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1899705173

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor

    Record identifier

    TN_cdi_proquest_journals_1899705173

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1899705173

    Share

    SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1899705173

    SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor

    Full title

    SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor

    Author / Creator

    Ye, Yumei ; Bajaj, Mandeep ; Yang, Hsiu-Chiung ; Perez-Polo, Jose R. ; Birnbaum, Yochai

    Publisher

    New York: Springer US

    Journal title

    Cardiovascular drugs and therapy, 2017, Vol.31 (2), p.119-132

    Record Identifier

    TN_cdi_proquest_journals_1899705173

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Activation Adamantane - analogs & derivatives Adamantane - pharmacology AMP-Activated Protein Kinases - metabolism Analysis Animals Apoptosis - drug effects Attenuation Augmentation Benzhydryl Compounds - pharmacology Blood sugar monitoring CARD Signaling Adaptor Proteins - antagonists & inhibitors CARD Signaling Adaptor Proteins - genetics CARD Signaling Adaptor Proteins - metabolism Cardiology Cardiomyopathy Caspase Caspase-1 Cells, Cultured Collagen Diabetes Diabetes mellitus Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - enzymology Diabetic Cardiomyopathies - enzymology Diabetic Cardiomyopathies - etiology Diabetic Cardiomyopathies - physiopathology Diabetic Cardiomyopathies - prevention & control Dipeptides - pharmacology Dipeptidyl Peptidase 4 - metabolism Dipeptidyl-Peptidase IV Inhibitors - pharmacology Disease Models, Animal Drug Therapy, Combination Echocardiography Fibroblasts - drug effects Fibroblasts - enzymology Fibrosis Glucose Glucose tolerance Glucose tolerance tests Glucosides - pharmacology Heart Heart function Hypoglycemic Agents - pharmacology In vitro methods and tests Inflammasomes Inflammasomes - antagonists & inhibitors Inflammasomes - genetics Inflammasomes - metabolism Inflammation Inflammation Mediators - metabolism Inhibitors Interleukin 1 Interleukin 6 Kidney Tubules, Proximal - drug effects Kidney Tubules, Proximal - metabolism Lipopolysaccharides Male Medicine Medicine & Public Health Mice Mice, Inbred C57BL Mice, Obese mRNA Myocytes, Cardiac - drug effects Myocytes, Cardiac - enzymology Myocytes, Cardiac - pathology NLR Family, Pyrin Domain-Containing 3 Protein - antagonists & inhibitors NLR Family, Pyrin Domain-Containing 3 Protein - genetics NLR Family, Pyrin Domain-Containing 3 Protein - metabolism Original Article Rodents Signal Transduction - drug effects Sodium-Glucose Transporter 2 - metabolism Sodium-Glucose Transporter 2 Inhibitors Stroke Volume - drug effects Time Factors Tumor necrosis factor Type 2 diabetes Ventricle Ventricular Function, Left - drug effects

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_journals_1899705173

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1899705173

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections